Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Apogee Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ACQUISITION DEEPENS ABBVIE'S ROBUST IMMUNOLOGY PIPELINE WITH DIVERSE ASSETS TARGETING DERMATOLOGIC, RESPIRATORY AND OTHER INFLAMMATORY AND IMMUNOLOGICAL DISEASES APOGEE'S LEAD ASSET, ZUMILOKIBART, IS A LATE-STAGE, HALF-LIFE EXTENDED MONOCLONAL ANTIBODY TARGETING IL-13, IN DEVELOPMENT FOR PATIENTS WITH ATOPIC DERMATITIS APOGEE'S PIPELINE ALSO INCLUDES APG273, A POTENTIAL BEST-IN-CATEGORY LONG-ACTING COMBINATION TARGETING IL-13 AND THYMIC STROMAL LYMPHOPOIETIN (TSLP), IN DEVELOPMENT FOR ASTHMA ABBVIE REAFFIRMS PREVIOUSLY ISSUED 2026 FULL-YEAR ADJUSTED DILUTED EPS GUIDANCE RANGE OF $13.87 - $14.07; REAFFIRMS PREVIOUSLY ISSUED THIRD-QUARTER ADJUSTED DILUTED EPS GUIDANCE RANGE OF $3.84 - $3.88 NORTH CHICAGO, ILL., SEPT. 3, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT IT HAS COMPLETED ITS ACQUISITION OF APOGEE THERAPEUTICS, INC. (NASDAQ: APGE).

ABBVIE COMPLETES ACQUISITION OF APOGEE THERAPEUTICS

ABBVIE TO ACQUIRE APOGEE FOR $135.11 PER SHARE IN CASH FOR TOTAL EQUITY VALUE OF APPROXIMATELY $10.9 BILLION, POSITIONING DIFFERENTIATED IMMUNOLOGY PORTFOLIO TO REACH MORE PATIENTS WORLDWIDE POSITIVE 16-WEEK PHASE 2 APEX PART B INDUCTION DOSE OPTIMIZATION RESULTS SUPPORT PLANNED ADVANCEMENT OF ZUMILOKIBART INTO PHASE 3 DEVELOPMENT IN MODERATE-TO-SEVERE ATOPIC DERMATITIS THIS YEAR SAN FRANCISCO AND BOSTON, AUG. 10, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH THE POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY REPORTED SECOND QUARTER 2026 FINANCIAL RESULTS, RECENT CORPORATE UPDATES AND PIPELINE PROGRESS. "THE SECOND QUARTER MARKED A TRANSFORMATIONAL PERIOD FOR APOGEE," SAID MICHAEL HENDERSON, M.D.

APOGEE REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND RECENT CORPORATE AND PIPELINE UPDATES

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF APOGEE THERAPEUTICS, INC. (NASDAQGM: APGE) TO ABBVIE (NYSE: ABBV). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF APOGEE WILL RECEIVE $135.11 IN CASH FOR EACH SHARE OF APOGEE THAT THEY OWN. KSF IS SEEKING TO DETERMINE WHETHER THIS CONSIDERATION AND THE PROCESS THAT LED TO IT ARE A.

APOGEE THERAPEUTICS INVESTOR ALERT: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF APOGEE THERAPEUTICS, INC. - APGE

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF APOGEE THERAPEUTICS, INC. (NASDAQGM: APGE) TO ABBVIE (NYSE: ABBV). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF APOGEE WILL RECEIVE $135.11 IN CASH FOR EACH SHARE OF APOGEE THAT THEY OWN. KSF IS SEEKING TO DETERMINE WHETHER THIS CONSIDERATION AND THE PROCESS THAT LED TO IT ARE ADEQUA.

PROPOSED ACQUISITION ADDS A DIVERSE PIPELINE OF ASSETS FOCUSED ON ELEVATING THE STANDARD OF CARE FOR PATIENTS WITH DERMATOLOGIC, RESPIRATORY AND OTHER RELATED INFLAMMATORY AND IMMUNOLOGICAL DISEASES APOGEE'S LEAD ASSET, ZUMILOKIBART (APG777), IS A LATE-STAGE, HALF-LIFE EXTENDED MONOCLONAL ANTIBODY TARGETING IL-13, IN DEVELOPMENT FOR PATIENTS WITH ATOPIC DERMATITIS APOGEE'S PIPELINE ALSO INCLUDES COMBINATIONS OF ITS NOVEL ANTIBODIES; APG273, A POTENTIAL BEST-IN-CATEGORY LONG-ACTING COMBINATION TARGETING IL-13 AND THYMIC STROMAL LYMPHOPOIETIN (TSLP), IS BEING DEVELOPED IN ASTHMA APOGEE SHAREHOLDERS TO RECEIVE $135.11 PER SHARE IN CASH, FOR A TOTAL EQUITY VALUE OF APPROXIMATELY $10.9 BILLION ABBVIE TO HOLD INVESTOR CONFERENCE CALL TODAY, JUNE 22, AT 8:00 A.M. CT NORTH CHICAGO, ILL.

ABBVIE TO ACQUIRE APOGEE THERAPEUTICS, DEEPENING IMMUNOLOGY PORTFOLIO

SAN FRANCISCO AND BOSTON, MAY 28, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), TODAY ANNOUNCED THAT MEMBERS OF MANAGEMENT WILL PARTICIPATE AT THE FOLLOWING INVESTOR CONFERENCES.

APOGEE THERAPEUTICS TO PARTICIPATE IN UPCOMING JUNE CONFERENCES

UP TO $1.3 BILLION IN FLEXIBLE, NON-DILUTIVE CAPITAL, INCLUDING UP TO $800 MILLION OF SYNTHETIC ROYALTY AND ACCESS OF UP TO $500 MILLION IN SENIOR CORPORATE DEBT

APOGEE THERAPEUTICS ANNOUNCES $1.3 BILLION STRATEGIC FINANCING COLLABORATION WITH BLACKSTONE LIFE SCIENCES TO ADVANCE PHASE 3 DEVELOPMENT AND COMMERCIALIZATION OF ZUMILOKIBART

APEX PART B MET ALL PRIMARY AND SECONDARY ENDPOINTS WITH HIGH STATISTICAL SIGNIFICANCE; MID-DOSE ZUMILOKIBART PLANNED TO ADVANCE INTO PHASE 3 TRIALS IN MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD) IN 2H 2026

APOGEE THERAPEUTICS ANNOUNCES POSITIVE 16-WEEK PART B INDUCTION DOSE OPTIMIZATION RESULTS FROM PHASE 2 APEX TRIAL OF ZUMILOKIBART IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

SAN FRANCISCO AND BOSTON, MAY 26, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY ANNOUNCED IT WILL REPORT PART B 16-WEEK DATA FROM THE PHASE 2 APEX TRIAL OF ZUMILOKIBART ON WEDNESDAY, MAY 27, 2026. FOLLOWING THE ANNOUNCEMENT, THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:00 A.M.

APOGEE THERAPEUTICS TO HOST CONFERENCE CALL TO REPORT PART B 16-WEEK DATA FROM THE PHASE 2 APEX TRIAL OF ZUMILOKIBART IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS ON MAY 27, 2026

ZUMILOKIBART ADVANCING ACROSS MULTIPLE INDICATIONS, WITH PHASE 3 INITIATION IN ATOPIC DERMATITIS (AD) EXPECTED LATER THIS YEAR: - APEX PHASE 2 PART A 52-WEEK DATA DEMONSTRATED DURABLE MAINTENANCE AND IMPROVED EFFICACY OVER TIME WITH EVERY 3- AND 6-MONTH DOSING IN MODERATE-TO-SEVERE AD - APEX PHASE 2 PART B 16-WEEK DATA IN AD EXPECTED IN Q2 2026 - FOLLOWING POSITIVE PHASE 1B ASTHMA RESULTS EARLIER THIS YEAR, EXPANSION PLANS ARE UNDERWAY WITH ADDITIONAL TRIAL DETAILS FOR ASTHMA AND EOSINOPHILIC ESOPHAGITIS (EOE) EXPECTED LATER THIS YEAR STRONG CASH POSITION OF $1.3B FOLLOWING SUCCESSFUL PUBLIC EQUITY OFFERING EXTENDING RUNWAY INTO 2029, THROUGH PLANNED BLA FILING FOR AD, SUBJECT TO REGULATORY ALIGNMENT SAN FRANCISCO AND BOSTON, MAY 11, 2026 (GLOBE NEWSWIRE) -- APOGEE THERAPEUTICS, INC. (NASDAQ: APGE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING OPTIMIZED, NOVEL BIOLOGICS WITH THE POTENTIAL FOR BEST-IN-CLASS PROFILES IN THE LARGEST INFLAMMATORY AND IMMUNOLOGY (I&I) MARKETS, TODAY PROVIDED PIPELINE PROGRESS AND REPORTED FIRST QUARTER 2026 FINANCIAL RESULTS. WE ARE OFF TO A RAPID START IN 2026, REFLECTING THE TEAM'S RELENTLESS FOCUS ON EXECUTION.

Apogee Therapeutics, Inc.

APGE

Price

Financial Reports

No items found.

Press Releases

Apogee Therapeutics, Inc.

APGE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

APGE